Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CD28-independent induction of experimental autoimmune encephalomyelitis
Tanuja Chitnis, Nader Najafian, Kald A. Abdallah, Victor Dong, Hideo Yagita, Mohamed H. Sayegh, Samia J. Khoury
Tanuja Chitnis, Nader Najafian, Kald A. Abdallah, Victor Dong, Hideo Yagita, Mohamed H. Sayegh, Samia J. Khoury
View: Text | PDF
Article

CD28-independent induction of experimental autoimmune encephalomyelitis

  • Text
  • PDF
Abstract

Experimental autoimmune encephalomyelitis (EAE) is a T cell–mediated disease initiated by antigen-specific CD4+ T cells. Signaling through CD28 is a critical second signal for activation of T cells, and CD28 knockout (CD28KO) mice have been reported to be resistant to induction of EAE. We now report that CD28KO mice have no intrinsic defect in mediating disease, because they developed EAE after passive transfer of primed T cells. After immunization, peripheral T cells from CD28KO mice were primed and developed memory phenotype, but had decreased antigen-specific IFN-γ production as compared with cells from wild-type (WT) animals. Reimmunization of CD28KO mice brought out clinical disease and increased IFN-γ production in vitro. Pathologically, there were cellular infiltrates in the central nervous system, in contrast to single-immunized mice. We show furthermore that blocking B7-1 or CTLA4, but not B7-2, in CD28KO mice induces disease after a single immunization. Thus, EAE can be induced in animals lacking CD28-dependent costimulation, suggesting that alternative costimulatory pathways were used. Blocking the OX40-OX40L costimulatory pathway differentially affected disease induction in CD28KO mice as compared with WT controls. Our data show that EAE may develop in the absence of CD28 T-cell costimulation. These findings have implications for therapies aimed at blocking costimulatory signals in autoimmune diseases.

Authors

Tanuja Chitnis, Nader Najafian, Kald A. Abdallah, Victor Dong, Hideo Yagita, Mohamed H. Sayegh, Samia J. Khoury

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
Increased IFN-γ production by MOG-reactive splenocytes in anti–B7-1–trea...
Increased IFN-γ production by MOG-reactive splenocytes in anti–B7-1–treated and anti-CTLA4–treated CD28KO mice. (a) IFN-γ production was measured by ELISA in the supernatants of splenocytes harvested on day 35 from C57BL/6 (open bars), CD28KO mice (gray bars), CD28KO mice treated with anti–B7-1 Ab (black bars), and CD28KO mice treated with anti-CTLA4 Ab (hatched bars). Cells were incubated with MOG p35-55 at concentrations of 1, 10, or 100 μg/ml. IFN-γ production was significantly increased in the anti–B7-1–treated CD28KO group (AP = 0.00006) and the anti-CTLA4–treated CD28KO group (P < 0.00009) compared with control Ig–treated CD28KO at the highest concentration of MOG. (b) MOG p35-55–specific IFN-γ–producing cells were measured by ELISPOT in cultures of splenocytes from C57BL/6 WT (open bars), or CD28KO mice (gray bars), or CD28KO mice treated with anti–B7-1 Ab (black bars), or CD28KO mice treated with anti-CTLA4 Ab (hatched bars), and harvested on day 35. The frequency of IFN-γ–producing cells was significantly greater in cultures from CD28KO mice treated with anti–B7-1 Ab (AP = 0.0007, BP = 0.0005, CP = 0.0011) and those treated with anti-CTLA4 than control CD28KO mice (P < 0.00001 at all concentrations of MOG peptide).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts